Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors.
Curigliano GiuseppeAndré B P van KuilenburgNicolas MachToshihiko DoiDavid TaiPatrick M FordeJohn SarantopoulosPhilippe L BedardChia-Chi LinF Stephen HodiSofie WilgenhofArmando SantoroCatherine A Sabatos-PeytonTyler A LongmireAlexandros XyrafasHaiying SunSabine GutzwillerLuigi ManentiAung NaingPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Sabatolimab plus spartalizumab was well tolerated and showed preliminary signs of antitumor activity. The RP2D for sabatolimab was selected as 800 mg Q4W (alternatively Q3W or Q2W schedules, based on modeling), with or without 400 mg spartalizumab Q4W.